Gloucestershire Hospitals NHS Foundation Trust
Gloucester, Gloucestershire, GL53 7AN, United Kingdom
NCT Number: NCT07816627
The investigator wants to investigate how big the differences are between measurements of the back of the eye taken by different OCT machines. The study is called: Applied Conversion Equation for Optical Coherence Tomography (ACE-OCT) study.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Gloucester, Gloucestershire, GL53 7AN, United Kingdom
Optical Coherence Tomography (OCT) is a type of scan of the back of the eye. It is non-invasive and provides vital information about the health of the eye. It is commonly available in optometrists and hospital eye units. OCT scans are a mainstay for deciding if treatment is needed for Diabetic Macular Oedema (DMO). However, there are many different companies that make these OCT machines and there is variability between the measurements. The amount of variability is unknown. Clinically, this means that patients may be under or over treated unknowingly. From a research perspective, patients are being excluded from studies because measurements from OCT different machines cannot be compared accurately.
There is a need for a conversion equation so measurements between OCT machines can be compared. This would be of benefit for patients, for clinicians making treatment decisions and for researchers
This project addresses the knowledge gap of not knowing the amount of variability in measurements between OCT machines. By knowing this, diseases such as DMO may possibly be detected and treated earlier. It will also make it easier to track progression of disease if a patient moves to a different treatment centre or OCT machine. Crucially, it will help research as patients will not be excluded if participants were scanned on different OCT machines.
The key objective of this study is to collect OCT images for 338 patients (675 eyes) with DMO at the same time and place on the two different OCT machines (Heidelberg Spectralis and Topcon Triton). This will comprise of 450 eyes (225 patients) for the training of the model and a further 225 eyes to validate the model.
Firstly, this will help the investigator to quantify the variability in the measurements between the machines. Secondly it will help the investigator to build a conversion equation for measurements taken on Heidelberg Spectralis and Topcon Triton OCT machines. The final stage is to validate the conversion equation to ensure that the model is suitable to be used.
There may be patients whose disease is under or overestimated due to variability in measurements on the different OCT machines. This project would mean that patients with DMO are diagnosed more accurately and treated is a timelier way which would positively affect their visual outcome.
This project will help further sight-saving research. It would mean that patients are not excluded from studies purely because their OCT images are not comparable as they were taken on different machines. Having more eligible patients for research studies would improve the quality of research into existing and new treatments and better inform treatment guidelines
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients had OCT scans with both the Heidelberg Spectralis and Topcon Triton machines.
Time frame: Through study completion, an average of 1 year
To calculate a conversion equation between two different OCT machines: Topcon Triton and Heidelberg Spectralis.
Gloucestershire Hospitals NHS Foundation Trust
Other
Acronym: ACE-OCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04576689
Diabetic Macular Oedema, Retinal Vein Occlusion with Macular Oedema
Hurstville, New South Wales, Australia
View Trial DetailsNCT02181400
Cardiovascular Diseases, Diabetes Complications
Sydney, New South Wales, Australia
View Trial DetailsNCT02554747
Diabetic Macular Oedema
Odense, Fyn, Denmark
View Trial DetailsNCT02457884
Diabetic Macular Oedema, Parafoveal Scotoma
Hong Kong, China
View Trial Details